0001628280-26-044884.txt : 20260623 0001628280-26-044884.hdr.sgml : 20260623 20260623160141 ACCESSION NUMBER: 0001628280-26-044884 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260622 FILED AS OF DATE: 20260623 DATE AS OF CHANGE: 20260623 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brumm Joshua T CENTRAL INDEX KEY: 0001528826 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36177 FILM NUMBER: 261110982 MAIL ADDRESS: STREET 1: ZELTIQ AESTHETICS INC. STREET 2: 4698 WILLOW ROAD SUITE 100 CITY: PLEASANTON STATE: CA ZIP: 94588 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CRESCENT BIOPHARMA, INC. CENTRAL INDEX KEY: 0001253689 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 FIFTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-430-5595 MAIL ADDRESS: STREET 1: 300 FIFTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: GLYCOMIMETICS INC DATE OF NAME CHANGE: 20030711 4 1 wk-form4_1782244898.xml FORM 4 X0609 4 2026-06-22 0 0001253689 CRESCENT BIOPHARMA, INC. CBIO 0001528826 Brumm Joshua T false C/O CRESCENT BIOPHARMA, INC. 300 FIFTH AVENUE WALTHAM MA 02451 1 1 0 0 Chief Executive Officer 1 Ordinary Shares 2026-06-22 4 S 0 42305 17.99 D 281212 D Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 28, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.88 to $18.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. /s/ Barbara Bispham, as attorney-in-fact for Joshua T. Brumm 2026-06-23